a Long term Specific Use Result Survey of TRASTUZUMAB BS for Intravenous Drip Infusion 60 mg and 150 mg 'Daiichi Sankyo'-A Long-term Use Survey in Patients with Gastric Cancer -
Latest Information Update: 19 Dec 2021
At a glance
- Drugs Trastuzumab (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 19 Dec 2021 Planned initiation date changed from 1 Jul 2019 to NULL.
- 19 Dec 2021 New trial record